COMMUNIQUÉS West-GlobeNewswire

Glow Peptide Stack Launched by Koi Peptides for Laboratory Use
11/06/2026
Cheyenne, WY, June 11, 2026 (GLOBE NEWSWIRE) -- Koi Peptides (Koi Research Labs LLC) has launched research-use-only Glow peptide stack, which combines three peptides, GHK-Cu, BPC-157, and TB-500, supplied as a [...]
Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
11/06/2026
Completion of patient dosing in the registrational Phase 2 clinical trial for 64 Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells Data [...]
Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap
11/06/2026
Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ). 1 HCP survey data suggests only around [...]
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
11/06/2026
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving [...]
Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026
11/06/2026
NEW YORK, 11 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
11/06/2026
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activation The vaccine antigens drive specific immune responses across different human immune profiles and induce targeted [...]
Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update
11/06/2026
Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented at WCN 2026 Pronounced [...]
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
11/06/2026
Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone 1 Nearly one in three patients with stage III colon [...]
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
11/06/2026
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous results Del-brax [...]
CARPL.ai Partners with Enlitic to Accelerate AI Validation for Imaging Customers
11/06/2026
CUPERTINO, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- CARPL.ai, the world's largest radiology AI marketplace and enterprise platform, today announced a partnership with Enlitic, to give imaging customers a stronger [...]
Glass House Brands Announces the Filing of Shelf Prospectus and At-The-Market Distribution Program
11/06/2026
LONG BEACH, Calif. and TORONTO, June 10, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“ Glass House ” or the “ Company ”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF) announced today that [...]
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
11/06/2026
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
11/06/2026
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Tilray Medical Allemagne lance ARX™, une nouvelle marque de cannabis médicinal haut de gamme cultivé en Allemagne
11/06/2026
La nouvelle marque associe des variétés éprouvées, l’expertise allemande en matière de culture et des normes de qualité rigoureuses au service des patients et des professionnels de santé dans toute l’Allemagne [...]
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
10/06/2026
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria -- -- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today [...]
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
10/06/2026
APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2 trial enrolled 191 [...]
Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients
10/06/2026
- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012’s primary endpoint and was observed to have [...]
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
10/06/2026
WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
10/06/2026
Company announcement – No. 24 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, June [...]

Pages